takeda

Zasocitinib Superior Efficacy to Deucravacitinib in Phase 3 Trial

Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete ...
takeda

FDA Approves MIMRYLO (rusfertide) for Polycythemia Vera

# Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of ...
takeda

FDA Approves ORZEYFUL for Adults With Narcolepsy Type 1

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a ...
takeda

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track | Takeda Pharmaceuticals

Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands Commercial execution and late-stage pipeline investments on schedule, ...
takeda

Takeda’s ORZEYFUL Approved in China for Narcolepsy Type 1

Shanghai, China — July 22, 2026 — Takeda China today announced that the National Medical Products Administration (NMPA) of China has approved the use of ORZEYFUL (oveporexton) for the treatment of ...
takeda

Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture ...

Osaka, JAPAN and CAMBRIDGE, Massachusetts, July 8, 2026 – Takeda (“Company”) today announced that it completed the issuance of new shares and disposal of treasury shares (“Issuance of Shares”) on July ...
takeda

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO | Takeda Pharmaceuticals

Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and assignments of directors OSAKA, Japan and CAMBRIDGE, ...
takeda

Oveporexton Phase 3 Results Show Benefits for Narcolepsy Type 1 Symptoms

# New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 "Narcolepsy type 1 is a 24-hour disease driven by orexin ...
takeda

Takeda Provides an Update regarding Jury Verdict in AMITIZA® (lubiprostone) Antitrust Litigation in the U.S. and Related Revision to FY2025 Financial Results | Takeda ...

OSAKA, Japan and CAMBRIDGE, Massachusetts, May 18, 2026 - Takeda (TSE:4502/NYSE:TAK) today announced that on May 18, 2026 (U.S. Eastern Time), a jury in the U.S. District Court for the District of ...
takeda

Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration OSAKA, Japan, May 13 ...